Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee
Mari Mino‐Kenudson, Kurt A. Schalper, Wendy A. Cooper, et al.
Journal of Thoracic Oncology (2022) Vol. 17, Iss. 12, pp. 1335-1354
Open Access | Times Cited: 113

Showing 26-50 of 113 citing articles:

Integrative analysis of single-cell and transcriptome sequencing with experimental validation reveals PKHD1L1 as a novel biomarker in lung adenocarcinoma
Xiangqian Zhang, Jie Wang, Hong Su, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Deregulated methylation and expression of PCDHGB7 in patients with non-small cell lung cancer: a novel prognostic and immunological biomarker
Yue Yuan, Xin Nie, Jiayi Gao, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Integrated analysis of M2 macrophage-related gene prognostic model and single-cell sequence to predict immunotherapy response in lung adenocarcinoma
Meifang Li, Zhiping Wang, Bin Huang, et al.
Frontiers in Genetics (2025) Vol. 16
Open Access
Multi-omics analysis reveals lysosome-associated molecular subtype characterization and prognostic modeling system in lung adenocarcinoma
Zhanmei Wang, Yan Wang, Jinxiang Wang
Journal of Cancer (2025) Vol. 16, Iss. 6, pp. 1794-1813
Open Access
AC129507.1 is a ferroptosis-related target identified by a novel mitochondria-related lncRNA signature that is involved in the tumor immune microenvironment in gastric cancer
Shanshan Yu, Jinxiao Liang, Lixiao Liu, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
EXO1's pan-cancer roles: diagnostic, prognostic, and immunological analyses through bioinformatics
Zheng Liu, Shu Huang, Rui Luo, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
PD-1/L1 immune checkpoint inhibitors for KRAS-mutant non-small cell lung cancer: a multicenter retrospective real-world study
K. Wei, Tiansheng Sun, Feng Xiao, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Involvement of GSK-3β, NF-κB, PPARγ, and apoptosis in amlodipine's anticancer effect in BALB/c mice
El‐Shaimaa A. Arafa, Maha M. Abdel‐Fattah, Emad H.M. Hassanein, et al.
Toxicology and Applied Pharmacology (2025), pp. 117298-117298
Closed Access
Overview on biomarkers for immune oncology drugs
Evgeny N. Imyanitov, Elena V. Preobrazhenskaya, Natalia V. Mitiushkina
Exploration of Targeted Anti-tumor Therapy (2025) Vol. 6
Open Access
Clinical and dynamic circulating cytokines profile features of long-term progression-free survival benefit to immune checkpoint inhibitors in advanced non–small cell lung cancer
Jia‐Yi Deng, Ming Gao, Xue Fan, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 6
Open Access
Smoking Cessation after Cancer Diagnosis and Enhanced Therapy Response: Mechanisms and Significance
Srikumar Chellappan
Current Oncology (2022) Vol. 29, Iss. 12, pp. 9956-9969
Open Access | Times Cited: 17
Prognostic and predictive biomarkers in non-small cell lung carcinoma
Igor Odintsov, Lynette M. Sholl
Pathology (2023) Vol. 56, Iss. 2, pp. 192-204
Closed Access | Times Cited: 9
A combined model of serum neutrophil extracellular traps, CD8+ T cells, and tumor proportion score provides better prediction of PD‐1 inhibitor efficacy in patients with NSCLC
Jian Guo, Tingting Shu, Hao Zhang, et al.
FEBS Journal (2024) Vol. 291, Iss. 15, pp. 3403-3416
Closed Access | Times Cited: 3
Single-cell and single-nucleus RNA-sequencing from paired normal-adenocarcinoma lung samples provide both common and discordant biological insights
Sébastien Renaut, Victoria Saavedra Armero, Dominique K. Boudreau, et al.
PLoS Genetics (2024) Vol. 20, Iss. 5, pp. e1011301-e1011301
Open Access | Times Cited: 3
Quantitative multiplexed imaging technologies for single-cell analysis to assess predictive markers for immunotherapy in thoracic immuno-oncology: promises and challenges
Edwin R. Parra, Marius Ilié, Ignacio I. Wistuba, et al.
British Journal of Cancer (2023) Vol. 129, Iss. 9, pp. 1417-1431
Closed Access | Times Cited: 8
Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor
Jia Yu, Fen Xiong, Yingruo Xu, et al.
International Immunopharmacology (2023) Vol. 127, pp. 111412-111412
Closed Access | Times Cited: 8
Dysregulation of SWI/SNF Chromatin Remodelers in NSCLC: Its Influence on Cancer Therapies including Immunotherapy
Yijiang Shi, Daniel Sanghoon Shin
Biomolecules (2023) Vol. 13, Iss. 6, pp. 984-984
Open Access | Times Cited: 7
Association between pretreatment C-reactive protein level and survival in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis
Haoyu Wang, Ruiyuan Yang, Ke Zhou, et al.
International Immunopharmacology (2023) Vol. 124, pp. 110937-110937
Closed Access | Times Cited: 7
5-Hydroxymethylcytosine in Cell-Free DNA Predicts Immunotherapy Response in Lung Cancer
Jianming Shao, Yitian Xu, Randall J. Olsen, et al.
Cells (2024) Vol. 13, Iss. 8, pp. 715-715
Open Access | Times Cited: 2
IFN-α/β/IFN-γ/IL-15 pathways identify GBP1-expressing tumors with an immune-responsive phenotype
Lei Wang, Yuxuan Wei, Jin Zheng, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Rediscovering immunohistochemistry in lung cancer
Anna La Salvia, May-Lucie Meyer, Fred R. Hirsch, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 200, pp. 104401-104401
Closed Access | Times Cited: 2
Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432)
Xinghao Ai, Bo Jia, Zhiyi He, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 2
Correlation of Programmed Death-Ligand 1 Expression With Lung Adenocarcinoma Histologic and Molecular Subgroups in Primary and Metastatic Sites
Kimon V. Argyropoulos, Atreyee Basu, Kyung Park, et al.
Modern Pathology (2023) Vol. 36, Iss. 9, pp. 100245-100245
Closed Access | Times Cited: 6
Utility of 18F-FDG uptake in predicting major pathological response to neoadjuvant immunotherapy in patients with resectable non‑small cell lung cancer
Xiaowei Chen, Guangyu Bai, Ruochuan Zang, et al.
Translational Oncology (2023) Vol. 35, pp. 101725-101725
Open Access | Times Cited: 6
Refining neoadjuvant immunotherapy for resectable lung cancer
Misty Dawn Shields, Christine M. Lovly
Nature Medicine (2024) Vol. 30, Iss. 6, pp. 1535-1536
Closed Access | Times Cited: 2

Scroll to top